Preparation and cytocompatibility of beta-calcium phosphate scaffolds with tanshinol coating

doi:10.3969/j.issn.2095-4344.2017.14.019

Abstract

Abstract:

BACKGROUND: Revascularization is a challenge for the tissue-engineered bone carrying cells after implanted into human body. Previous studies have found that tanshinol can improve the functions of endothelial progenitor cells and exert vascular protective effects.
OBJECTIVE: To prepare the β-calcium phosphate (β-TCP) scaffold with tanshinol coating, and to observe its cytocompatibility.
METHODS: The β-TCP scaffolds coated with 10^-7, 10^-6and 10^-5 mol of tanshinol were constructed by negative pressure absorption method. The distribution of tanshinol coating on the scaffold was observed using scanning electron microscopy, and the inner ingredients were analyzed by infrared spectrum. Human endothelial progenitor cells (hEPCs) were cultured in the extracts of β-TCP and β-TCP scaffolds with 10^-7, 10^-6, 10^-5 mol of tanshinol coatings, respectively. The cell proliferation was detected at 2, 4, 6, 8 and 10 days of culture; the levels of nitric oxide and vascular endothelial growth factor in the supernatants were detected at 1, 7 and 14 days of culture; the lumen formation on the matrigel was observed after 14-day culture. hEPCs were respectively seeded onto the β-TCP and β-TCP scaffolds with different dosages of tanshinol coating, and then the cell growth was observed under scanning electron microscope at 7 days.
RESULTS AND CONCLUSION: The tanshinol coating evenly distributed on the inner surface of the pores, and its crystalline structure became dense with dosage increasing. Infrared spectrum analysis revealed no changes in the characteristic absorption peak of tanshinol and TCP in the scaffold. The β-TCP scaffolds with tanshinol coating could promote the proliferation of hEPCs, especially the scaffolds with 10^-6 and 10^-5 mol tanshinol coating. Compared with the β-TCP scaffold, the scaffolds with 10^-6 and 10^-5 mol tanshinol coating significantly upregulated the nitric oxide level at 14 days of culture, and significantly increased the level of vascular endothelial growth factor at 7 and 14 days of culture (P < 0.05). Although it could be found in all β-TCP scaffolds with tanshinol coating, the lumen formation was the maturest in the scaffold with 10^-5 mol tanshinol coating. These results suggest the β-TCP scaffolds with tanshinol coating can promote the proliferation and endothelial differentiation of hEPCs, and hold a good cytocompatibility.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Calcium Phosphates, Endothelial Cells, Tissue Engineering

CLC Number:

R318

Wu Tao, Liu Ying-chao, Nan Kai-hui, Shu Tao, Wu Jin-hui, Lu Zhi-qin, Xing Jian-zhou, Lv Jun. Preparation and cytocompatibility of beta-calcium phosphate scaffolds with tanshinol coating[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(14): 2247-2253.

Figures/Tables 3

References

[1]Dew L,Macneil S,Chong CK.Vascularization strategies for tissue engineers.Regen Med.2015;10(2):211-224.

[2]Shastri VP.Future of regenerative medicine: challenges and hurdles.Artif Organs. 2006;30:828-834.

[3]周苗,彭歆,车月娟,等.构建预制个性化骨瓣修复下颌骨缺损的灵长类动物模型[J].中国组织工程研究, 2014,18(18):2812-2817.

[4]Zhou M,Peng X,Mao C,et al.Primate mandibular reconstruction with prefabricated, vascularized tissue-engineered bone flaps and recombinant human bone morphogenetic protein-2 implanted in situ.Biomaterials.2010; 31(18):4935-4943.

[5]孟宪勇,杨新明,彭阿钦,等.以带蒂筋膜瓣为膜材料应用GBR 技术修复兔骨缺损的血管化作用及成骨方式研究[J].生物骨科材料与临床研究,2010,7(5):10-15.

[6]孔劲松,陈振光,郑晓晖,等.带血管蒂组织瓣预构组织工程骨血管化的研究[J].武汉大学学报(医学版),2008,29(1):34-37.

[7]孙勇,肖建德.血管内皮生长因子在骨组织工程中的应用[J].国际骨科学杂志,2007,28(6): 393-397.

[8]Poldervaart MT,Gremmels H,Deventer KV,et al.Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture.J Control Release. 2014; 184(1):58-66.

[9]Sharmin F,McDermott C,Lieberman J,et al.Dual growth factor delivery from biofunctionalized allografts: Sequential VEGF and BMP-2 release to stimulate allograft remodeling.J Orthop Res.2016.doi: 10.1002/jor.23287. [Epub ahead of print]

[10]Barati D,Shariati SR,Moeinzadeh S,et al.Spatiotemporal release of BMP-2 and VEGF enhances osteogenic and vasculogenic differentiation of human mesenchymal stem cells and endothelial colony-forming cells co-encapsulated in a patterned hydrogel. J Control Release.2016;223:126-136

[11]Poynton AR,Lane JM.Safety profile for the clinical use of bone morphogenetic proteins in the spine.Spine.2002;27(16 Suppl 1):S40-48.

[12]Christensen TJ,Annis P,Hohl JB,et al.Neuroforaminal chondrocyte metaplasia and clustering associated with recombinant bone morphogenetic protein-2 usage in transforaminal lumbar interbody fusion.Spine J.2014;14(6):e23-e28.

[13]Poon B,Kha T,Tran S,et al.Bone morphogenetic protein-2 and bone therapy: successes and pitfalls.J Pharm Pharmacol. 2016;68(2):139-147.

[14]Kim MJ,Kim KM,Kim J,et al.BMP-2 promotes oral squamous carcinoma cell invasion by inducing CCL5 release.PlOs One. 2014;9(10):e108170-e108170.

[15]Li L,Zhou X,Li N,et al.Herbal drugs against cardiovascular disease: traditional medicine and modern development.Drug Discov Today.2015;20(9):1074-1086.

[16]Chang CC,Lee YC,Lin CC,et al.Characteristics of traditional Chinese medicine usage in patients with stroke in Taiwan: A nationwide population-based study.J Ethnopharmacol. 2016; 186:311-321.

[17]Yang Y,Chin A,Zhang L,et al.The Role of Traditional Chinese Medicines in Osteogenesis and Angiogenesis.Phytother Res. 2014;28(1):1-8.

[18]Wong RW,Rabie AB.Traditional Chinese Medicines and Bone Formation—A Review. J Oral Maxillofac Surg.2006;64(5): 828-837.

[19]Yao Y,Feng Y,Wang L.Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris. Int J Cardiol.2015;182:46-47.

[20]Qian S,Wang S,Fan P,et al.Effect of Salvia miltiorrhiza, Hydrophilic Extract on the Endothelial Biomarkers in Diabetic Patients with Chronic Artery Disease.Phytother Res.2012; 26(26):1575-1578.

[21]Chen J,Lv Q,Yu M,et al.Randomized clinical trial of Chinese herbal medications to reduce wound complications after mastectomy for breast carcinoma.Br J Surg. 2010;97(12): 1798-1804.

[22]王军,张藜莉,吴戈,等.中西药物联合应用于介入综合治疗股骨头缺血性坏死的临床研究[J].中国中西医结合杂志, 2007,27(9): 800-803.

[23]黄相杰,姜红江,刘德忠,等.磷酸钙骨水泥/丹参缓释系统植入治疗股骨头缺血性坏死[J].中国修复重建外科杂志，2008,22(3): 307-310.

[24]王昌兴,沈建国,姜滔,等.持续局部丹参和肝素灌注治疗股骨头坏死疗效分析[J].中国骨伤,2010,23(5):383-385.

[25]Wu D,Lei Y,Tong Y,et al.Angiogenesis of the Frozen-Thawed Human Fetal Ovarian Tissue at the Early Stage After Xenotransplantation and the Positive Effect of Salviae miltiorrhizae.Anat Rec (Hoboken). 2010;293(12):2154-2162.

[26]孟华,朱妙章,郭军,等.中药当归、川芎、丹参提取液促血管生成作用的实验研究[J].中药材,2006,29(6):574-576.

[27]高冬,宋军,胡娟,等. 活血化瘀中药对鸡胚绒毛尿囊膜血管生成的影响[J].中国中西医结合杂志,2005,25(10):912-915.

[28]Lay IS,Chiu JH,Shiao MS,et al.Crude extract of Salvia miltiorrhiza and salvianolic acid B enhance in vitro angiogenesis in murine SVR endothelial cell line.Planta Medica.2003;69(1):26-32.

[29]Du G,Zhu H,Yu P,et al.SMND-309 promotes angiogenesis in human umbilical vein endothelial cells through activating erythropoietin receptor/STAT3/VEGF pathways. Eur J Pharmacol. 2012;700:173-180.

[30]Zhou X,Chan SW,Tseng HL,et al.Danshensu is the major marker for the antioxidant and vasorelaxation effects of Danshen (Salvia miltiorrhiza) water-extracts produced by different heat water-extractions. Phytomedicine. 2012;19(14):1263-1269.

[31]Wu T, Nan KH,Chen JD,et al.A new bone repair scaffold combined with chitosan/hydroxyapatite and sustained releasing icariin.Chin Sci Bull. 2009;54(17):2953-2961.

[32]Chan K,Chui SH,Wong DYL,et al.Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction.Life Sci.2004;75(26):3157-3171.

[33]Yang GD,Zhang H,Lin R,et al.Down-Regulation of CD40 Gene Expression and Inhibition of Apoptosis with Danshensu in Endothelial Cells.Basic Clin Pharmacol Toxicol.2009;104(2):87-92.

[34]陆广汇.丹参素对外周血内皮祖细胞增殖、粘附和迁移功能的影响[J].中国医药导刊, 2012,14(2):784-785.

[35]肖刚峰,张怀勤,季亢挺,等.丹参素对体外培养内皮祖细胞数量和功能的影响[J].华西药学杂志,2006,21(3):232-234.

[36]Wang L,Fan H,Zhang ZY,et al.Osteogenesis and angiogenesis of tissue-engineered bone constructed by prevascularized β-tricalcium phosphate scaffold and mesenchymal stem cells. Biomaterials.2010;31(36):9452-9461.

[37]Mifune Y,Matsumoto T,Kawamoto A,et al.Local delivery of granulocyte colony stimulating factor-mobilized CD34-positive progenitor cells using bioscaffold for modality of unhealing bone fracture.Stem Cells.2008;26(6):1395-1405.

[38]Herrmann M,Binder A,Menzel U,et al.CD34/CD133 enriched bone marrow progenitor cells promote neovascularization of tissue engineered constructs in vivo.Stem Cell Res.2014;13(3):465-477.

[39]Fu WL,Xiang Z,Huang FG,et al.Coculture of peripheral blood-derived mesenchymal stem cells and endothelial progenitor cells on strontium-doped calcium polyphosphate scaffolds to generate vascularized engineered bone.Tissue Eng Part A.2014;21(5-6):948-959.

[40]Li R,Nauth A,Gandhi R,et al.BMP-2 mRNA expression after endothelial progenitor cell therapy for fracture healing.Journal of Orthop Trauma.2014;28 Suppl 1(4):S24-27.

[41]Vandevord PJ,Yang SY.Frontiers | Promotion of osteogenesis in tissue-engineered bone by pre-seeding endothelial progenitor cells-derived endothelial cells.J Orthop Res. 2008; 26(8):1147-1152.

[42]Kong Z,Li J,Zhao Q,et al.Dynamic compression promotes proliferation and neovascular networks of endothelial progenitor cells in demineralized bone matrix scaffold seed.J Appl Phys.2012;113(4):619-26.